Vectibix® (panitumumab). Full prescribing information. Amgen Inc., Thousand Oaks, CA, 2017.
Vectibix (panitumumab). Summary of product characteristics. Amgen Europe B.V., Breda, Netherlands, 2018.
Battaglin F, Puccini A, Ahcene Djaballah S, et al. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. Cancer Manag Res. 2019;11:5911–24.
Hendrikx J, Haanen J, Voest EE, et al. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212–21.
Hendrikx JJMA, Beijnen JH, Huitema ADR. Is bodyweight-based dosing truly better than flat dosing for panitumumab? [Letter]. Clin Pharmacol Adv Appl. 2020;12:177–8.
Liao MZ, Berkhout M, Prenen H, et al. Dose regimen rationale for panitumumab in cancer patients: to be based on body weight or not. Clin Pharmacol. 2020;12:109–14.
Mitchell RA, Luwor RB, Burgess AW. Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics. Exp Cell Res. 2018;371(1):1–19.
Koveitypour Z, Panahi F, Vakilian M, et al. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;9:97.
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809.
Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999;59(6):1236–43.
Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38(1):17–23.
Voigt M, Braig F, Gothel M, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia. 2012;14(11):1023–31.
Center for Drug Evaluation and Research. Vectibix® (Panitumumab), application number 125147/0 (Clinical Pharmacology and Biopharmaceutics Review). 2006. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125147s0000_ClinPharmR.pdf. Accessed 1 Nov 2020.
Freeman DJ, Bush T, Ogbagabriel S, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther. 2009;8(6):1536–46.
Freeman DJ, McDorman K, Ogbagabriel S, et al. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer. 2012;11:47.
Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010;184(1):512–20.
Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1277–81.
Ma P, Yang BB, Wang YM, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol. 2009;49(10):1142–56.
Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22(15):3003–15.
Weiner LM, Belldegrun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008;14(2):502–8.
Yang BB, Lum P, Chen A, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet. 2010;49(11):729–40.
Krens LL, Baas JM, Guchelaar HJ, et al. Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease. Cancer Chemother Pharmacol. 2018;81(1):179–82.
Krens LL, Baas JM, de Jong FA, et al. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer Chemother Pharmacol. 2014;73(2):429–33.
Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359–72.
Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6(6):427–32.
Yang BB, Wu CY, Chen E, et al. Pharmacokinetics of irinotecan with and without panitumumab coadministration in patients with metastatic colorectal cancer. Clin Pharmacol Drug Dev. 2013;2(3):205–12.
Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis. Eur J Cancer Suppl. 2005;3(2):324.
Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110(5):980–8.
Ketzer S, Schimmel K, Koopman M, et al. Clinical pharmacokinetics and pharmacodynamics of the epidermal growth factor receptor inhibitor panitumumab in the treatment of colorectal cancer. Clin Pharmacokinet. 2018;57(4):455–73.
Hendrikx J, Beijnen JH, Huitema ADR. Is bodyweight-based dosing truly better than flat dosing for panitumumab? [Letter]. Clin Pharmacol. 2020;12:177–8.
Liao MZ, Kast J, Berkhout M, et al. Is bodyweight-based dosing truly better than flat dosing for panitumumab? [Response to letter]. Clin Pharmacol Adv Appl. 2020;12:189–90.
European Medicines Evaluation Agency. Vectibix: scientific discussion. Amsterdam, the Netherlands: European Medicines Agency; 2007. Accessed 21 Dec 2020.
Mitchell EP, Hecht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis. J Clin Oncol. 2007;25(18_suppl):4082.
Muro K, Yoshino T, Doi T, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2009;39(5):321–6.
Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–64.
Crawford J, Swanson P, Schwarzenberger P, et al. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2013;8(12):1510–8.
Messersmith WA, Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res. 2007;13(16):4664–6.
Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006;29(1):1–9.
Lofgren JA, Dhandapani S, Pennucci JJ, et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol. 2007;178(11):7467–72.
Weeraratne D, Chen A, Pennucci JJ, et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol. 2011;11:17.